Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy with Pembrolizumab and IL-2 in Advanced Colorectal Cancer
NCT06530303Phase 2Recruiting
- Sponsor
- Essen BioTech
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in colorectal cancer (CRC), sponsored by Essen BioTech. Started Sep 2024; status: recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06530303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06530303.